Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Dose-escalation, Dose-optimization and Dose Expansion Study to Evaluate the Safety and Preliminary Efficacy of Tri-specific Antibody (SOA101) in Subjects With Advanced Solid Tumors.

NCT07055594 is registered in ClinicalTrials.gov with Shine-On Biomedical Co., Ltd. as lead sponsor.

NCT NCT07055594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Dose-escalation, Dose-optimization and Dose Expansion Study to Evaluate the Safety and Preliminary Efficacy of Tri-specific Antibody (SOA101) in Subjects With Advanced Solid Tumors.
Lead sponsor
Shine-On Biomedical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
December 31, 2028
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors